| EP方案治疗复发或难治性晚期弥漫大B细胞淋巴瘤的疗效观察 |
| |
| 引用本文： | 笪洁,杜瀛瀛,熊福星,刘虎. EP方案治疗复发或难治性晚期弥漫大B细胞淋巴瘤的疗效观察[J]. 安徽医药, 2010, 14(1): 58-59. DOI: 10.3969/j.issn.1009-6469.2010.01.024 |
| |
| 作者姓名： | 笪洁 杜瀛瀛 熊福星 刘虎 |
| |
| 作者单位： | 安徽医科大学第一附属医院肿瘤内科,安徽,合肥,230022;安徽医科大学第一附属医院肿瘤内科,安徽,合肥,230022;安徽医科大学第一附属医院肿瘤内科,安徽,合肥,230022;安徽医科大学第一附属医院肿瘤内科,安徽,合肥,230022 |
| |
| 摘 要： | 目的 评价Vp-16联合DDP治疗复发或难治性的晚期弥漫大B细胞淋巴瘤的有效性与安全性。方法观察30例明确诊断的晚期弥漫大B细胞淋巴瘤患者，男20例，女10例，系既往行CHOP方案治疗无效或缓解后半年内复发者，KPS〉60分，予Vp-16100mg·m^-2静脉滴注第1～3天，DDP25mg·m^-2静脉滴注第1～3天，每三周重复，化疗2周期后评价治疗的有效性和安全性。结果30例患者中有2例因第1周期治疗出现严重骨髓抑制退出未能评价疗效，28例可评价患者中CR7．1％（2／28），PR25％（7／28），SD32．2％（9／28），PD35．7％（10／28），疾病缓解率（CR＋PR）32．1％。骨髓抑制是剂量限制性毒性，其他主要毒副反应为脱发、恶心、呕吐、静脉炎、疲劳等。结论EP方案治疗复发或难治性晚期弥漫大B细胞淋巴瘤有较高的疾病控制率，用药方便，安全性较好，值得临床推广应用。
|
| 关 键 词： | EP 弥漫大B细胞淋巴瘤 治疗 |
EP chemotherapy regimen for the treatment of recurrent or refractory late staged DLBCL patients |
| |
| DA Jie,DU Ying-ying,XIONG Fu-xing,LIU Hu. EP chemotherapy regimen for the treatment of recurrent or refractory late staged DLBCL patients[J]. Anhui Medical and Pharmaceutical Journal, 2010, 14(1): 58-59. DOI: 10.3969/j.issn.1009-6469.2010.01.024 |
| |
| Authors: | DA Jie DU Ying-ying XIONG Fu-xing LIU Hu |
| |
| Affiliation: | Dept of Oncology;The First Affiliated Hospital of Anhui Medical University;Hefei;Anhui 230022 |
| |
| Abstract: | Aim To evaluate the therapeutic efficacies and side effects of Vp-16 combined with DDP(EP regimen) in the treatment of recurrent or recalcitrant late staged diffuse large B-cell lymphoma(DLBCL) patients.Methods The study was conducted on 30 patients with recurrent or recalcitrant late staged DLBCL,who had showed recalcitrant with CHOP regimen,or relapsed in six months.All the patients had been confirmed with pathology.The study included 20 male patients and 10 female ones,KPS>60.All patients received intrav... |
| |
| Keywords: | EP DLBCL chemotherapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
